HSDT (Helius Medical Technologies Inc.) Return on Sales by Gross Profit

HSDT (Helius Medical) - company brandmark

Optimizing the distribution of wearable neurodevices through a partner network minimizes logistical risks and supports high profitability for Helius Medical (HSDT). The net gross margin illustrates cost management efficiency, with the metric holding at 92.80. The technological status of PoNS ensures the leadership of Helius Medical (HSDT), despite slow insurance coverage. Growth is expected to be driven by new treatment indications and the expansion of its commercial presence.

Helius Medical Technologies (HSDT): Gross Margin from 07/04/2022 to 11/19/2026

Financial and market metric breakdowns for Helius Medical Technologies Inc. (HSDT)

Basic company analysis:HSDT - Helius Medical
Finished products of Helius Medical Technologies, Inc.

Helius Medical (HSDT) transitioning to a SaaS model for PoNS device software support creates potential for a sharp increase in profitability due to the scalability of digital services. Analyzing the company's gross profit margin, an investor sees the portion of revenue minus direct production costs, where an upward trend confirms operational efficiency, while extreme peaks signal a risk of stock overvaluation.

Direct competitors

Return on Gross Profit Biogen Corp|Return on Gross Profit NBIX|Regencell Corp (RGC) - Return on Sales by Gross Profit|Gross Margin AXSM|Return on Gross Profit ACADIA Pharmaceuticals ACAD|Gross Margin XENE (Xenon Pharmaceuticals Inc.)|VKTX (Viking Therapeutics, Inc.) - Gross Profitability Margin|SUPN - Gross Profitability|Catalyst Pharmaceuticals Inc (CPRX) - Return on Gross Profit|DNLI (Denali Corp) - Return on Gross Profit|Gross Profit Margin harmonybiosciences.com (HRMY)|Return on Gross Profit BHVN|Gross Margin Amylyx|Gross Margin TRVI|PRAX (Praxis Corp) - Gross Profit Rate|Gross Margin AVXL (anavex.com)|CBLL: Gross Return on Sales|PRTA - Gross Profitability|ALEC - Gross Margin|Annexon Inc. (ANNX) - Gross Profitability|Return on Gross Profit Omeros Corp|Return on Gross Profit NGNE|ACIU: Gross Profit Rate|Return on Gross Profit VYGR (Voyager Corp)|Return on Gross Profit Neumora NMRA|Gross Profitability Scilex Holding Company, Inc. SCLX|Gross Sales Margin Tevogen Bio Inc.|ACOG - Gross Profitability|Gross Sales Margin Cognition Therapeutics (CGTX)|IKT (Inhibikase Therapeutics) - Return on Gross Profit|Cassava Sciences Inc (SAVA) - Gross Margin|Return on Gross Profit ASRT|Gross Margin coyatherapeutics.com|Gross Margin VTGN|Ovid Therapeutics - Gross Return on Sales|Gross Margin ABOS (Acumen Pharmaceuticals, Inc)|CRVO - Return on Gross Profit|ATHE - Gross Profitability|Return on Sales by Gross Profit clene.com CLNN|PEPG: Gross Margin|Gross Return on Sales JUNS|RLMD (Relmada Corp) - Gross Margin|Annovis Bio Inc (ANVS) - Return on Sales by Gross Profit|Gross Profitability Grace Therapeutics, Inc. (GRCE)|AIFF (Firefly Neuro) - Gross Profit Rate|Gross Profitability Klotho Neurosciences KLTO|NRSN: Gross Return on Sales|RVPH: Return on Gross Profit|MTVA: Gross Profitability|NRXS (NeurAxis Inc) - Return on Gross Profit|PASG - Return on Sales by Gross Profit|Gross Profitability Neuphoria Therapeutics, Inc.|Gross Profitability NERV|Gross Margin ATHA|ADXN (Addex Therapeutics Ltd) - Gross Profit Rate|Gross Profitability alzamend.com ALZN|Return on Sales by Gross Profit Cyclerion Therapeutics (CYCN)|Protagenic - Gross Margin|Gross Profit Rate KTTA (Pasithea Therapeutics Corp)|CRGT: Gross Margin|Avenue Therapeutics Inc. (ATXI) - Gross Margin|BCLI (BrainStorm Cell Therapeutics Inc.) - Gross Margin|Gross Margin Cara Therapeutics Inc|Gross Profitability Chromocell Therapeutics (CHRO)|Gross Profit Ratio ELYM|Gross Profitability Intra-Cellular ITCI|LBPH: Gross Return on Sales|MRNS - Gross Profitability|NKGen Biotech, Inc. (NKGN) - Return on Gross Profit|neurobopharma.com (NRBO) - Gross Profitability|SAGE: Gross Profit Ratio|Gross Profitability Synaptogenix, Inc.|Gross Profitability TRVN|Gross Margin VIGL|Gross Margin anewmeds.com (WENA)|Gross Margin CERE (cerevel.com)